×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CHRS – coherus biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CHRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
09:30 am
chrs
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/6
08:27 am
chrs
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer [Yahoo! Finance]
High
Report
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer [Yahoo! Finance]
1/6
08:00 am
chrs
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
Medium
Report
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
1/5
09:30 am
chrs
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Medium
Report
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
12/8
08:30 am
chrs
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Low
Report
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
11/7
09:00 am
chrs
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Low
Report
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
11/6
04:14 pm
chrs
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
11/6
01:54 pm
chrs
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Low
Report
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:14 pm
chrs
coherus biosciences, inc.
BEAT
Report
-10.1%
coherus biosciences, inc.
5/12/2025
04:15 pm
chrs
coherus biosciences, inc.
BEAT
Report
-19.9%
coherus biosciences, inc.
3/10/2025
04:12 pm
chrs
coherus biosciences, inc.
BEAT
Report
-3.7%
coherus biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/9
06:03 am
chrs
Form EFFECT Coherus Oncology, Inc.
Low
Report
Form EFFECT Coherus Oncology, Inc.
11/6
05:12 pm
chrs
Form 10-Q Coherus Oncology, Inc. For: Sep 30
Medium
Report
Form 10-Q Coherus Oncology, Inc. For: Sep 30
11/6
04:29 pm
chrs
Form 8-K Coherus Oncology, Inc. For: Nov 06
High
Report
Form 8-K Coherus Oncology, Inc. For: Nov 06
11/4
06:45 pm
chrs
Form SCHEDULE 13G Coherus Oncology, Inc. Filed by: Bering Partners II, L.P.
Low
Report
Form SCHEDULE 13G Coherus Oncology, Inc. Filed by: Bering Partners II, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Q2/2019 6/30/2019 EPS 0.320 ZacksConsensus -0.080 ActVsEst 0.400 - Beat
17.6%
11/6 Form 8-K Coherus BioSciences, For: Nov 06 16.9%
1/13 Form 4 Coherus BioSciences, For: Jan 09 Filed by: HEALY JAMES 14.4%
2/27 Form 8-K Coherus BioSciences, For: Feb 27 13.8%
5/9 Form 8-K Coherus BioSciences, For: May 09 9.6%
3/24 Coherus Biosciences Inc (NASDAQ: CHRS) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating. 9.4%
4/20 Coherus Biosciences: Worth The Risks [Seeking Alpha] 7.9%
8/21 Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 7.0%
3/1 Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock. 7.0%
3/20 Coherus BioSciences Announces New Employment Inducement Grants 6.5%
11/6 Form 8-K Coherus BioSciences, For: Nov 06 16.9%
1/13 Form 4 Coherus BioSciences, For: Jan 09 Filed by: HEALY JAMES 14.4%
2/27 Form 8-K Coherus BioSciences, For: Feb 27 13.8%
5/9 Form 8-K Coherus BioSciences, For: May 09 9.6%
3/24 Coherus Biosciences Inc (NASDAQ: CHRS) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating. 9.4%
4/20 Coherus Biosciences: Worth The Risks [Seeking Alpha] 7.9%
8/21 Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 7.0%
3/1 Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock. 7.0%
3/20 Coherus BioSciences Announces New Employment Inducement Grants 6.5%
TOP News Decliners
7/8
Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million
-14.3%
5/7 Coherus Biosciences Inc (NASDAQ: CHRS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock. -7.9%
11/25 Form 4 Coherus BioSciences, For: Nov 21 Filed by: Lanfear Dennis M -7.8%
9/25 Form 4 Coherus BioSciences, For: Sep 23 Filed by: Viret Jean-Frederic -7.4%
4/14 Form 8-K Coherus BioSciences, For: Apr 13 -6.4%
5/24 Form 4 Coherus BioSciences, For: May 22 Filed by: HEALY JAMES -5.8%
10/22 Form 4 Coherus BioSciences, For: Oct 18 Filed by: Viret Jean-Frederic -5.5%
3/5 Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 -5.0%
5/10 Coherus Biosciences Inc (NASDAQ: CHRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
1/13 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States -4.1%
5/7 Coherus Biosciences Inc (NASDAQ: CHRS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock. -7.9%
11/25 Form 4 Coherus BioSciences, For: Nov 21 Filed by: Lanfear Dennis M -7.8%
9/25 Form 4 Coherus BioSciences, For: Sep 23 Filed by: Viret Jean-Frederic -7.4%
4/14 Form 8-K Coherus BioSciences, For: Apr 13 -6.4%
5/24 Form 4 Coherus BioSciences, For: May 22 Filed by: HEALY JAMES -5.8%
10/22 Form 4 Coherus BioSciences, For: Oct 18 Filed by: Viret Jean-Frederic -5.5%
3/5 Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 -5.0%
5/10 Coherus Biosciences Inc (NASDAQ: CHRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
1/13 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: